Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003332 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00003332 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 36 participants.
The verdict
NCT00003332, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with radiation therapy and/or surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy, consisting of gemcitabine and cisplatin, followed by chemotherapy and radiation therapy and/or surgery in treating patients who have pancreatic cancer.
Interventions
- DRUG cisplatin
- RADIATION radiation therapy
- DRUG gemcitabine hydrochloride
- PROCEDURE surgical procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1997-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003332
The ClinicalTrials.gov registry entry for NCT00003332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00003332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003332 about?
NCT00003332 is a clinical study titled "Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with radiation therapy and/or surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy, con...
What is the current status of trial NCT00003332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 1997-07.
What interventions are being tested in trial NCT00003332?
The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), gemcitabine hydrochloride (DRUG), surgical procedure (PROCEDURE).
Who is sponsoring clinical trial NCT00003332?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.